Case number 1:23-cv-00581
Vertex Pharmaceuticals Incorporated v. Lupin Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 27, 2023 | 11 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,564,916 B2. (Attachments: # 1 Order)(nms) (Entered: 11/27/2023) (0) |
| Jul 18, 2023 | 10 | REDACTED VERSION of 8 Letter, by Vertex Pharmaceuticals Incorporated. (Fahnestock, Derek) Modified on 7/19/2023 (nms). (Entered: 07/18/2023) (2) |
| Jul 10, 2023 | 9 | ORAL ORDER: The request to consolidate (D.I. 7 in 23-cv-582-RGA; D.I. 7 in 23-cv-581-RGA; D.I. 190 in 20-cv-988-RGA-CJB; D.I. 7 in 23-cv-666-RGA) is GRANTED. These actions are consolidated for all purposes including trial, and all filings shall be made in C.A. No. 20-988-RGA-CJB ONLY. All requests to amend the scheduling order will be handled by Magistrate Judge Christopher J. Burke. Ordered by Judge Richard G. Andrews on 7/10/2023. Associated Cases: 1:20-cv-00988-RGA-CJB, 1:23-cv-00581-RGA, 1:23-cv-00582-RGA, 1:23-cv-00666-RGA(nms) (Entered: 07/10/2023) (0) |
| Jul 7, 2023 | 7 | Joint Stipulation and [Proposed] Order to Consolidate and Amend Scheduling Order, by Vertex Pharmaceuticals Incorporated. (Fahnestock, Derek) Modified on 7/10/2023 (nms). (Entered: 07/07/2023) (18) |
| Jul 7, 2023 | 8 | [SEALED] Letter to The Honorable Richard G. Andrews, from Derek J. Fahnestock, regarding proposed consolidated scheduling order. (Fahnestock, Derek) Modified on 7/10/2023 (nms). (Entered: 07/07/2023) (0) |
| May 26, 2023 | 1 | Complaint* (1) |
| May 26, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jdb) (Entered: 05/26/2023) (3) |
| May 26, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 26, 2023. Date of Expiration of Patent: August 13, 2029. (jdb) (Entered: 05/26/2023) (1) |
| May 26, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,564,916 B2. (jdb) (Entered: 05/26/2023) (1) |
| May 26, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Vertex Pharmaceuticals Incorporated. (jdb) (Entered: 05/26/2023) (1) |
| May 26, 2023 | 6 | Summons Issued as to Lupin Pharmaceuticals, Inc. and Lupin Limited on 5/26/2023. (Attachments: # 1 Summons Issued Lupin Limited)(jdb) (Entered: 05/26/2023) (Main Document) (2) |
| May 26, 2023 | 6 | Summons Issued as to Lupin Pharmaceuticals, Inc. and Lupin Limited on 5/26/2023. (Attachments: # 1 Summons Issued Lupin Limited)(jdb) (Entered: 05/26/2023) (Summons Issued Lupin Limited) (2) |
